Please login to the form below
trastuzumab
This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.
AZ strengthens Daiichi Sankyo partnership with new ADC deal
acalabrutinib) and its recently approved, Daiichi-partnered HER2-targeting ADC, Enhertu (trastuzumab deruxtecan).
Latest news
-
Roche cites COVID-19 and biosimilars in Q2 decline
Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
-
EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug
AZ/Daiichi’s drug gained US Food and Drug Administration (FDA) approval for trastuzumab deruxtecan in December under the brand name Enhertu. ... Trastuzumab deruxtecan is central to Daiichi’s growth efforts, and is also a key drug for AZ’s cancer
-
Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) can be administered by subcutaneous (SC) injection in minutes, compared to hours with intravenous (IV) administration using the current single-agent formulations, says
-
Seattle Genetics wins FDA priority review for oral HER2 drug
Seattle is seeking approval for tucatinib in combination with Roche’s anti-HER2 antibody (trastuzumab) plus Xeloda (capecitabine). ... ado-trastuzumab emtansine).
-
AZ revenues rise, but it says coronavirus could hit 2020
However, the FDA approval of Daiichi Sankyo-partnered HER2 drug Enhertu (trastuzumab deruxtecan) for breast cancer – tipped as a $4.5bn blockbuster by some analysts – came too late to register any
More from news
Approximately 14 fully matching, plus 166 partially matching documents found.
Latest Intelligence
-
Surviving cancer: a new era for patients
The rise of the monoclonal antibody. Trastuzumab was the first monoclonal antibody tested in clinical trials, designed to inhibit human epidermal growth factor receptor 2 (HER2) which, when activated, promotes breast ... Trastuzumab successfully reduced
-
Cortellis Drugs to Watch in 2020 report
10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2.
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... 4. Daiichi Sankyo. The fourth company on our list – Daiichi Sankyo – has something in common with the first.Our
-
2016: The year when deal-makers took stock?
Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .
-
Deal Watch October 2016
Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
AVEO's financial head joins ImmunoGen
cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Are biobetters a market access opportunity?
trastuzumab emtansine), received its first EU approval. for HER2+ metastatic breast cancer patients who did not respond to Herceptin and/or taxane.
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
Roche’s Kadcyla (trastuzumab emtansine). the Committee stated that while it demonstrates relevant survival benefit, its use as second-line treatment of metastatic disease was considered not to be a priority
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- FDA hands BMS and bluebird bio a priority review for ide-cel
- 20 for 2020 – Five pharma companies to watch
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
